Eli Lilly and Company (LLY)vsPureTech Health PLC (PRTC)
LLY
Eli Lilly and Company
$1,115.70
-0.65%
HEALTHCARE · Cap: $994.92B
PRTC
PureTech Health PLC
$17.42
0.00%
HEALTHCARE · Cap: $419.90M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 1709838% more annual revenue ($79.67B vs $4.66M). LLY leads profitability with a 33.5% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
PRTC
Avoid30
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Reasonable price relative to book value
Earnings expanding 61.5% YoY
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 29.4x book value
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -30.8% — below average capital efficiency
Revenue declined 38.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : PRTC
The strongest argument for PRTC centers on Price/Book, EPS Growth.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : PRTC
The primary concerns for PRTC are Market Cap, Profit Margin, Return on Equity.
Key Dynamics to Monitor
LLY profiles as a growth stock while PRTC is a value play — different risk/reward profiles.
PRTC carries more volatility with a beta of 0.79 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 30/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →PureTech Health PLC
HEALTHCARE · BIOTECHNOLOGY · USA
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops and markets drugs for inflammatory, fibrotic and immune, intractable, lymphatic and gastrointestinal, neurological and neuropsychological cancers and other diseases in the United States. The company is headquartered in Boston, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?